Loading…
Loading…
FDXF (FedEx Freight Holding Company, Inc.) is a recent IPO.
It began trading on June 1, 2026, giving it a few months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
FDXF pairs scale, pricing tools and growth targets with high debt, soft demand and spin-off execution risks, making it a hold currently.
I assign FedEx Freight Holding Company a buy rating, driven by early signs of freight recovery and substantial spare capacity. FDXF's high fixed-cost base and 30% available terminal capacity enable outsized profit leverage as shipment volumes normalize. Dimensional pricing and a fully staffed LTL sales force are set to enhance yield and capture higher-margin demand during the upcycle.
FedEx Freight Holding Company Inc. (NYSE:FDXF) received renewed support from Bank of America (BofA) following its first earnings report as a standalone company, with the brokerage reiterating its Buy rating and raising its price forecast to $187 from $185.
Shares of FedEx Freight (FDXF) experienced a decline following its first earnings report as an independent entity. The report revealed a 4.8% year-over-year rev
FedEx Freight Holding Company, Inc. (FDXF) Q4 2026 Earnings Call Transcript
The company expects revenue to grow 4% to 6% for June 1 to Dec. 31, and said the outlook reflects its confidence in the underlying strength of the business.
MEMPHIS, Tenn.--(BUSINESS WIRE)--Q4 FY2026 Earnings Release.
Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reportedly concluded after renewed threats against Iran from President Trump and continued attacks in Lebanon by Israel made for an eventful first day of talks; earnings from FedEx and Micron are on tap this week, along with the release of the Fed's preferred measure of inflation; SpaceX shares are poised to start this week with a third straight day of declines; and shares of Apogee Therapeutics are soaring on news it is being acquired by AbbVie for $11 billion. Here's what you need to know today.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for FDXF and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.